How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? incretin versus insulin treatment

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  Gallwitz, Baptist ^a   Bretzel, Reinhard G ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SULFONYLUREA; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGLYCEMIA; END STAGE RENAL DISEASE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIFESTYLE; LIPOTOXICITY; META ANALYSIS (TOPIC); METABOLIC REGULATION; NAUSEA; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; LIFE STYLE; PATIENT CARE PLANNING; PATIENT-CENTERED CARE; RISK REDUCTION BEHAVIOR;

EID: 84891802218     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2012     Document Type: Article

References (72)

1. International Diabetes Federation. Diabetes atlas [article online], 2011. Available from http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed 14 December 2012
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
3. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591
4. U.S. Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011
5. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyper-glycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
6. Gallwitz B, Guzman J, Dotta F, et al. Ex-enatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with met-formin failure (EUREXA): an open-label, randomised controlled trial. Lancet 2012; 379:2270-2278
7. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dys-glycemia. N Engl J Med 2012;367:319-328
8. Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247-1258
9. Gallwitz B. Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 2011;71: 1675-1688
10. Gallwitz B. Benefit-risk assessment of ex-enatide in the therapy of type 2 diabetes mellitus. Drug Saf 2010;33:87-100
11. Garber AJ. Liraglutide in oral antidiabetic drug combination therapy. Diabetes Obes Metab 2012;14(Suppl. 2):13-19
12. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide-1 receptor agonistsdavailable efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011;13:394-407
13. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286
14. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
15. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
16. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569
17. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metfor-min: a non-inferiority study. Diabetologia 2007;50:259-267
18. Barnett AH, Burger J, Johns D, et al. Tol-erability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-2348
19. Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 2009;25:65-75
20. Gallwitz B, Böhmer M, Segiet T, et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 2011; 34:604-606
21. Bunck MC, Cornér A, Eliasson B, et al. Effects of exenatide on measures of b-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2041-2047
22. Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly ex-enatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012;35:683-689
23. Russell-Jones D, Vaag A, Schmitz O, et al.; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglu-tide vs insulin glargine and placebo in combination with metformin and sulfo-nylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-2055
24. Wang Y, Li L, Yang M, Liu H, Boden G, Yang G. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials. Diabetes Obes Metab 2011;13: 972-981
25. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results-A Long Term Evaluation (LEADER) [article online], 2012. Available from http://clinicaltrials.gov/ct2/show/NCT01179048. Accessed 17 June 2012
26. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus [article online]. Available from http://www.clinicaltrials.gov/ct2/show/NCT01144338. Accessed 17 June 2012
27. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
28. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009;373: 2215-2221
29. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258
30. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998;15:290-296
31. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-110
32. Meier JJ, Breuer TGK, Bonadonna RC, et al. Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans. Diabetologia 2012;55: 1346-1354
33. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009;26: 1185-1192
34. Bolli GB, Lucidi P, Porcellati F, Fanelli CG. Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes. Diabetes Care 2011;34(Suppl. 2):S220-S224
35. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on (3-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760
36. Retnakaran R, Drucker DJ. Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet 2008;371:1725-1726
37. Dandona P, Chaudhuri A, Mohanty P, Ghanim H. Anti-inflammatory effects of insulin. Curr Opin Clin Nutr Metab Care 2007;10:511-517
38. Vehkavaara S, Yki-Järvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2004;24:325-330
39. Kellerer M, Lammers R, Häring HU. Insulin signal transduction: possible mechanisms for insulin resistance. Exp Clin Endocrinol Diabetes 1999;107:97-106
40. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976;42: 222-229
41. Pennartz C, Schenker N, Menge BA, Schmidt WE, Nauck MA, Meier JJ. Chronic reduction of fasting glycemia with insulin glargine improves first-and second-phase insulin secretion in patients with type 2 diabetes. Diabetes Care 2011; 34:2048-2053
42. Forst T, Larbig M, Hohberg C, et al. Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial b-cell protection in individuals with type 2 diabetes. Diabetes Obes Metab 2010;12:437-441
43. Vinik A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 2009;29:1236-1253
44. Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357: 1716-1730
45. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-1084
46. Ludvik B, Brath H, Wascher T, Toplak H; Expertengruppe der Osterreichischen Diabetesgesellschaft. The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus. Wien Klin Wochenschr 2009;121:473-482 [in German]
47. Linn T, Fischer B, Soydan N, et al. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:3839-3846
48. Bretzel RG, Dippel FW, Linn T, Neilson AR. Comparison of treatment costs in inadequately controlled type 2 diabetes in Germany based on the APOLLO trial with insulin glargine. J Media Econ 2009;12:1-11
49. Peyrot M, Rubin RR, Lauritzen T, et al.; The International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;29:952-953
50. Bretzel RG, Eckhard M, Landgraf W, Owens DR, Linn T. Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents: basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care 2009;32(Suppl. 2):S260-S265
51. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidi-abetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410-1418
52. Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypo-glycaemia. Diabetes Obes Metab 2011;13: 814-822
53. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
54. Gerstein HC, Yale J-F, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23: 736-742
55. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451
56. Yki-Järvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titra-tion and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007;30:1364-1369
57. Kennedy L, Herman WH, Strange P, Harris A; GOAL AIC Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care2006;29: 1-8
58. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidia-betic treatment: an observational study of everyday practice in 12, 216 patients. Diabetes Obes Metab 2007;9:31-38
59. Schreiber SA, Ferlinz K, Haak T. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther 2008; 10:121-127
60. Hanefeld M, Fleischmann H, Landgraf W, Pistrosch F. EARLY study: early basal insulin therapy under real-life conditions in type 2 diabetics. Diabetes Stoffw Herz 2012;21:91-97
61. Vergès B, Brun JM, Tawil C, Alexandre B, Kerlan V. Strategies for insulin initiation: insights from the French LIGHT observational study. Diabetes Metab Res Rev 2012;28:97-105
62. Odawara M, Ohtani T, Kadowaki T. Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study sub-analysis. Diabetes Technol Ther 2012;14: 635-643
63. The ORIGIN Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155: 26-32
64. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375: 2215-2222
65. Rydén L, Standl E, Bartnik M, et al.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136
66. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target, 7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012;14: 228-233
67. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enoughdwhat next? Diabetes Metab Res Rev 2007;23:257-264
68. Lebovitz HE, Banerji MA. Non-insulin injectable treatments (glucagon-like pep-tide-1 and its analogs) and cardiovascular disease. Diabetes Technol Ther 2012;14 (Suppl. 1):S43-S50
69. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009;31:1511-1523
70. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010;33: 1509-1515
71. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes. Ann Intern Med 2011;154: 1-11
72. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration? Dia-betologia 2009;52:1219-1226